NO20054048L - Ftalazinderivater for behandling av inflammatoriske sykdommer - Google Patents
Ftalazinderivater for behandling av inflammatoriske sykdommerInfo
- Publication number
- NO20054048L NO20054048L NO20054048A NO20054048A NO20054048L NO 20054048 L NO20054048 L NO 20054048L NO 20054048 A NO20054048 A NO 20054048A NO 20054048 A NO20054048 A NO 20054048A NO 20054048 L NO20054048 L NO 20054048L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- disease
- phthalazine derivatives
- inflammatory diseases
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Det er beskrevet behandling av en inflammatorisk sykdom, spesielt en inflammatorisk reumatoid eller reumatisk sykdom, og/eller smerte med en inhibitor av aktiviteten av VEGF-reseptortyrosinkinase av formel I hvori r er 0 til 2, n er 0 til 3, R1 o g R2 er a) uavhengig i hvert tilfelle en lavere alkyl, b) danner sammen en bro av underforrnel I* hvori bindingen oppnås via de to terminale C-atomene og m er 0 til 4, eller c) danner sammen en bro av underformel I** hvori ett eller to av ringelementene T1, T2, T3 og T4 er nitrogen, og de andre er i hvert tilfelle CH, og bindingen oppnås via atomer T1 og T4, G er -C(=O)-, -CHF-, -CF2-, lavere alkylen, C2-C6-alkenylen, lavere alkylen eller C3-C6-alkenylen substituert med acyloksy eller hydroksy, -CH2-0-, -CH2-S-, -CH2-NH-, -CH2-O-CH2-, -CH2-S-CH2-, -CH2-NH-CH2-, oksa (-O-), tia (-S-), imino (-NH-), -CH2-O-CH2-, -CH2-S-CH2- eller -CH2-NH-CH2-, A, B, D, E og T er uavhengig N eller CH under den forutsetning at minst én og ikke mer enn tre av disse restene er N, Q er lavere alkyl, lavere alkoksy eller halogen, Ra og Ra' er hver uavhengig H eller lavere alkyl, X er imino, oksa eller tia, Y er hydrogen, aryl, heteroaryl eller usubstituert eller substituert sykloalkyl, og Z er mono- eller disubstituert amino, halogen, alkyl, substituert alkyl, hydroksy, foretret eller forestret hydroksy, nitro, cyano, karboksy, forestret karboksy, alkanoyl, karbamoyl, N-mono- eller N,N-disubstituert karbamoyl, amidino, guanidino, merkapto, sulfo, fenyltio, fenyl-laverealkyltio, alkylfenyltio, fenylsulfinyl, fenyl-laverealkylsulfinyl, alkylfenylsulfinyl, fenylsulfonyl, fenyl-laverealkylsulfonyl, alkylfenylsulfonyl eller (altemativt eller, i en videre forstand av oppfinnelsen, i tillegg) valgt fra gruppen bestående av ureido, halogen-laverealkyltio, halogen-laverealkansulfonyl, pyrazolyl, lavere-alkylpyrazolyl og C2-C7-alkenyl; hvori dersom mer enn 1| rest Z (rn > 2) er til stede - substituentene Z er valgt uavhengig av hverandre; og hvor bindingene angitt i underformel I* med en bølget linje, enten er enkelt- eller dobbeltbindinger; eller et N-oksid av nevnte forbindelse, hvori 1 eller flere N-atomer bærer et oksygenatom; eller et farmasøytisk akseptabelt salt derav; så vel som nye ftalazinderivater; fremgangsmåter for fremtilling derav; anvendelsen derav i en fremgangsmåte for behandling av det humane eller animalske legeme; anvendelsen derav for behandling av en sykdom, spesielt en sykdom forårsaket ved okular neovaskularisering, så som aldersrelatert makular degenerering eller diabetisk retinopati, eller andre sykdommer som viser respons på inhiberingen av tyrosinkinaser, sa som en proliferativ sykdom; en fremgangsmåte for behandling av slik sykdom i pattedyr; og anvendelsen av en slik forbindelse for fremstilling av et farmasøytisk preparat for behandling spesielt av en sykdom som nevnt ovenfor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH60399 | 1999-03-30 | ||
GBGB9916064.0A GB9916064D0 (en) | 1999-07-08 | 1999-07-08 | Organic compounds |
PCT/EP2000/002726 WO2000059509A1 (en) | 1999-03-30 | 2000-03-28 | Phthalazine derivatives for treating inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20054048L true NO20054048L (no) | 2001-10-19 |
Family
ID=25685089
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014655A NO320849B1 (no) | 1999-03-30 | 2001-09-25 | Anvendelse av ftalazinderivat for fremstilling av et farmasoytisk preparat |
NO20052893A NO20052893D0 (no) | 1999-03-30 | 2005-06-14 | Ftalazinderivater for behandling av inflammatoriske sykdommer |
NO20054048A NO20054048L (no) | 1999-03-30 | 2005-08-31 | Ftalazinderivater for behandling av inflammatoriske sykdommer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014655A NO320849B1 (no) | 1999-03-30 | 2001-09-25 | Anvendelse av ftalazinderivat for fremstilling av et farmasoytisk preparat |
NO20052893A NO20052893D0 (no) | 1999-03-30 | 2005-06-14 | Ftalazinderivater for behandling av inflammatoriske sykdommer |
Country Status (13)
Country | Link |
---|---|
US (4) | US6686347B2 (no) |
EP (1) | EP1165085B1 (no) |
JP (1) | JP4673977B2 (no) |
CN (2) | CN1221262C (no) |
AT (1) | ATE329596T1 (no) |
AU (1) | AU766081B2 (no) |
BR (1) | BR0009507A (no) |
CA (1) | CA2366857C (no) |
DE (1) | DE60028740T2 (no) |
ES (1) | ES2265929T3 (no) |
NO (3) | NO320849B1 (no) |
PT (1) | PT1165085E (no) |
WO (1) | WO2000059509A1 (no) |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0981343T3 (da) | 1997-05-14 | 2006-01-30 | Atherogenics Inc | Probucolmonoestere til behandling af kardiovaskulær og inflammatorisk sygdom |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
EP1165085B1 (en) * | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
US6689883B1 (en) | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
DOP2000000070A (es) * | 1999-09-28 | 2002-02-28 | Bayer Healthcare Llc | Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis |
US7977333B2 (en) | 2000-04-20 | 2011-07-12 | Bayer Healthcare Llc | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
HUP0302173A2 (hu) | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
DE60130017T2 (de) * | 2000-11-22 | 2008-05-15 | Novartis Ag | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
ES2265452T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
EP1363702A4 (en) * | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
ES2705016T3 (es) | 2001-02-19 | 2019-03-21 | Novartis Int Pharmaceutical Ag | Derivado de rapamicina para el tratamiento de cáncer de pulmón |
GB0111078D0 (en) | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
BR0209647A (pt) | 2001-05-16 | 2004-07-27 | Novartis Ag | Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003028711A2 (en) * | 2001-09-27 | 2003-04-10 | Novartis Ag | Use of c-kit inhibitors for the treatment of myeloma |
US7819875B2 (en) * | 2002-02-08 | 2010-10-26 | Gursharan Singh Chana | Surgical devices and methods of use |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
NZ560662A (en) | 2002-05-16 | 2009-09-25 | Novartis Ag | Use of EDG receptor binding agents in cancer |
WO2004013140A1 (en) | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
MXPA05003161A (es) * | 2002-09-24 | 2005-09-12 | Novartis Ag | Uso de derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. |
WO2004033042A1 (en) * | 2002-10-10 | 2004-04-22 | Novartis Ag | Treatment of amm |
US7326690B2 (en) * | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
AU2003286373A1 (en) * | 2002-12-20 | 2004-07-14 | Dana-Farber Cancer Institute Inc. | Treatment of von hippel lindau disease |
ITMI20022739A1 (it) * | 2002-12-23 | 2004-06-24 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4. |
TW200505442A (en) | 2003-05-19 | 2005-02-16 | Genomics Inst Of The Novartis Res Foundation | Immunosuppressant compounds and compositions |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
CN103880955A (zh) | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
WO2006034441A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
WO2006034341A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
AU2006294850A1 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of HDAC dependent diseases |
ES2481671T3 (es) | 2005-11-21 | 2014-07-31 | Novartis Ag | Inhibidores de mTOR en el tratamiento de tumores endocrinos |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
US7989631B2 (en) | 2006-02-10 | 2011-08-02 | Amgen Inc. | Hydrate forms of AMG706 |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
JP2009536180A (ja) | 2006-05-09 | 2009-10-08 | ノバルティス アクチエンゲゼルシャフト | 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用 |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
WO2008061108A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
RU2009134223A (ru) | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用 |
SG182205A1 (en) * | 2007-03-15 | 2012-07-30 | Novartis Ag | Organic compounds and their uses |
US8252840B2 (en) | 2007-03-26 | 2012-08-28 | Salutria Pharmaceuticals Llc | Methods of derivatives of probucol for the treatment of type II diabetes |
WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
AU2009327405A1 (en) | 2008-12-18 | 2011-06-30 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
SG171785A1 (en) | 2008-12-18 | 2011-07-28 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
BRPI0922466A2 (pt) | 2008-12-18 | 2018-10-23 | Novartis Ag | sais |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
EP2393361B1 (en) | 2009-02-06 | 2016-12-07 | Bach Pharma, Inc. | Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them |
KR101360725B1 (ko) | 2009-06-26 | 2014-02-07 | 노파르티스 아게 | Cyp17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
IN2012DN01961A (no) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
US20120149661A1 (en) | 2009-08-26 | 2012-06-14 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
EP2475668A1 (en) | 2009-09-10 | 2012-07-18 | Novartis AG | Ether derivatives of bicyclic heteroaryls |
MY156209A (en) | 2009-11-04 | 2016-01-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful mek inhibitors |
US20120289501A1 (en) | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
EP2509964B1 (en) | 2009-12-08 | 2014-04-30 | Novartis AG | Heterocyclic sulfonamide derivatives |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
EP2683722A1 (en) | 2011-03-08 | 2014-01-15 | Novartis AG | Fluorophenyl bicyclic heteroaryl compounds |
DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
MX2013014398A (es) | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
BR112014015308A2 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
EA201491259A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
CA2859869A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
MX2014007731A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
RU2660354C2 (ru) | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
CN107207510B (zh) | 2014-07-31 | 2019-11-29 | 诺华股份有限公司 | 联合疗法 |
EP3242934B1 (en) | 2015-01-08 | 2021-08-18 | The Board of Trustees of the Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
JOP20190154B1 (ar) | 2016-12-22 | 2022-09-15 | Amgen Inc | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
EP3697425A1 (en) | 2017-10-18 | 2020-08-26 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
JP7021356B2 (ja) | 2017-12-21 | 2022-02-16 | ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
CA3117221A1 (en) | 2018-11-16 | 2020-05-22 | Amgen Inc. | Improved synthesis of key intermediate of kras g12c inhibitor compound |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
CN113226473A (zh) | 2018-12-20 | 2021-08-06 | 美国安进公司 | Kif18a抑制剂 |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
JP2022542392A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
KR20220100903A (ko) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
MX2022005708A (es) | 2019-11-14 | 2022-06-08 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ,インコーポレイテッド | Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
CN112110790B (zh) * | 2020-09-28 | 2023-06-23 | 台州臻挚生物科技有限公司 | 一种3,5-二卤三氟甲苯及3`-氯-5`-(三氟甲基)苯基三氟乙酮的制备方法 |
WO2022061918A1 (zh) * | 2020-09-28 | 2022-03-31 | 杭州臻挚生物科技有限公司 | 一种3,5-二卤三氟甲苯及3'-氯-5'-(三氟甲基)苯基三氟乙酮的制备方法 |
WO2022165173A1 (en) * | 2021-01-28 | 2022-08-04 | The Scripps Research Institute | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2960504A (en) * | 1957-05-07 | 1960-11-15 | Ciba Pharm Prod Inc | 1-hydrazino, 4-pyridyl methyl-phthalazines |
BE567431A (no) | 1957-05-07 | |||
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
US4665181A (en) * | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
JPH01261386A (ja) * | 1988-04-11 | 1989-10-18 | Nisshin Flour Milling Co Ltd | 新規な2―ピリジルメチルチオ誘導体及びそれを含有する抗潰瘍剤 |
ES2224130T3 (es) * | 1994-08-09 | 2005-03-01 | Eisai Co., Ltd. | Compuesto de piridazina condensada. |
JP3919835B2 (ja) * | 1994-08-09 | 2007-05-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリダジン系化合物 |
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
JPH10218791A (ja) * | 1997-01-31 | 1998-08-18 | Toagosei Co Ltd | 慢性関節リウマチ治療薬 |
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
ATE371453T1 (de) * | 1998-08-13 | 2007-09-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von okularen neovaskularen erkrankungen |
EP1165085B1 (en) * | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
-
2000
- 2000-03-28 EP EP00920604A patent/EP1165085B1/en not_active Expired - Lifetime
- 2000-03-28 AU AU41125/00A patent/AU766081B2/en not_active Ceased
- 2000-03-28 CA CA2366857A patent/CA2366857C/en not_active Expired - Fee Related
- 2000-03-28 JP JP2000609072A patent/JP4673977B2/ja not_active Expired - Fee Related
- 2000-03-28 BR BR0009507-9A patent/BR0009507A/pt active Pending
- 2000-03-28 WO PCT/EP2000/002726 patent/WO2000059509A1/en active IP Right Grant
- 2000-03-28 ES ES00920604T patent/ES2265929T3/es not_active Expired - Lifetime
- 2000-03-28 CN CNB008057370A patent/CN1221262C/zh not_active Expired - Fee Related
- 2000-03-28 CN CN2004101046723A patent/CN1660840A/zh active Pending
- 2000-03-28 PT PT00920604T patent/PT1165085E/pt unknown
- 2000-03-28 AT AT00920604T patent/ATE329596T1/de active
- 2000-03-28 DE DE60028740T patent/DE60028740T2/de not_active Expired - Lifetime
-
2001
- 2001-09-25 NO NO20014655A patent/NO320849B1/no not_active IP Right Cessation
- 2001-09-26 US US09/964,025 patent/US6686347B2/en not_active Expired - Fee Related
-
2003
- 2003-11-26 US US10/723,238 patent/US6911440B2/en not_active Expired - Fee Related
-
2005
- 2005-04-05 US US11/099,292 patent/US20050176711A1/en not_active Abandoned
- 2005-06-14 NO NO20052893A patent/NO20052893D0/no unknown
- 2005-08-31 NO NO20054048A patent/NO20054048L/no not_active Application Discontinuation
-
2006
- 2006-05-26 US US11/441,961 patent/US7329660B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2366857C (en) | 2010-12-14 |
EP1165085B1 (en) | 2006-06-14 |
ES2265929T3 (es) | 2007-03-01 |
AU766081B2 (en) | 2003-10-09 |
NO320849B1 (no) | 2006-02-06 |
US20060217388A1 (en) | 2006-09-28 |
US6686347B2 (en) | 2004-02-03 |
CA2366857A1 (en) | 2000-10-12 |
JP2002541108A (ja) | 2002-12-03 |
DE60028740D1 (de) | 2006-07-27 |
US20030013718A1 (en) | 2003-01-16 |
DE60028740T2 (de) | 2007-05-24 |
BR0009507A (pt) | 2002-01-15 |
EP1165085A1 (en) | 2002-01-02 |
US20050176711A1 (en) | 2005-08-11 |
JP4673977B2 (ja) | 2011-04-20 |
AU4112500A (en) | 2000-10-23 |
PT1165085E (pt) | 2006-10-31 |
NO20052893L (no) | 2001-10-19 |
NO20014655D0 (no) | 2001-09-25 |
ATE329596T1 (de) | 2006-07-15 |
CN1221262C (zh) | 2005-10-05 |
CN1660840A (zh) | 2005-08-31 |
NO20014655L (no) | 2001-10-19 |
US7329660B2 (en) | 2008-02-12 |
US6911440B2 (en) | 2005-06-28 |
US20040142934A1 (en) | 2004-07-22 |
CN1367695A (zh) | 2002-09-04 |
NO20052893D0 (no) | 2005-06-14 |
WO2000059509A1 (en) | 2000-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052893L (no) | Ftalazinderivater for behandling av inflammatoriske sykdommer | |
MA32167B1 (fr) | Dérivés d'imidazo[1,2-b]pyridazine pour le traitement de maladies médiées par la tyrosine kinase c-met | |
EA200900388A1 (ru) | Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus | |
NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
BR0311221A (pt) | Derivados de 1h-imidazo[4,5-c]quinolina no tratamento de doenças dependentes de proteìna cinase | |
NO20063758L (no) | Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer | |
ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
NO20052733L (no) | C-6 modifiserte indazolylpyrrolotriaziner | |
BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
WO2004071447A3 (en) | Substituted azole derivatives as therapeutic agents | |
DOP2005000014A (es) | Derivados 1h-tieno[2, 3-c] pirazol utiles como inhibidores de quinasa | |
ATE365550T1 (de) | Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie | |
UY38766A (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
ATE396986T1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
TN2020000160A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
PE20030714A1 (es) | Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf | |
ATE444069T1 (de) | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen | |
KR102023748B1 (ko) | 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물 | |
EA038087B1 (ru) | Трехкомпонентная фармацевтическая комбинация чистых антагонистов 5-ht6 рецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора, применение указанной комбинации и содержащей ее фармацевтической композиции в лечении когнитивных расстройств и способ такого лечения | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
GB0111078D0 (en) | Organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |